Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
GLP-1 receptor agonists Primary mechanism(s) of action Increase glucose-dependent insulin secretion, reduce post-prandial glucagon, and delay gastric emptying (resulting in reduced after meal glucose levels and increased satiety) Examples Exenatide (Byetta 10 mcg Pen, Byetta 5 mcg Pen, Bydureon BCise 2 mcg Pen) Dosage Immediate release (Byetta) Initial: 5 mcg subcutaneous injection twice daily a maximum of 60 minutes before morning and evening meals, or before the two main meals of the day Maximum: 10 mcg subcutaneous injection twice daily a maximum of 60 minutes before morning and evening meals, or before the two main meals of the day Extended release (Bydureon BCise) Initial: 2 mg subcutaneous injection once weekly Maximum: 2 mg subcutaneous injection weekly Lixisenatide (Adlyxin) Short-acting Dosage Initial: 10 mcg subcutaneous injection once daily, up to one hour before the first meal of the day, for 14 days
Zhang, Y., Chen, R., Jia, Y., Chen, M
Whats Coming Next for GLP-1 and Metabolic Disease Treatment Moving from academia to industry led to advancing groundbreaking diabetes and obesity therapies
We review your history and check your B12 level so treatment is based on your actual numbers, not a guess
Verdict: Limited evidence human endocrine studies are small or indirect, and DSIP has not been proven as an anxiety or cortisol-lowering therapy [810]
US$ 21.61
US$ 23.52
US$ 20.64
US$ 27.71
